Neurocrine Biosciences CRENESSITY Shows Sustained Benefits in Two-Year Pediatric CAH Study

Key Takeaways

• 60% of overweight/obese pediatric CAH patients showed clinically meaningful BMI improvements at two years
• 61% of patients with baseline insulin resistance no longer showed insulin resistance after treatment
• CRENESSITY enabled sustained hormone control while reducing glucocorticoid exposure in children

---

Neurocrine Biosciences announced positive two-year data for CRENESSITY® (crinecerfont) in pediatric patients with classic congenital adrenal hyperplasia (CAH), demonstrating sustained clinical benefits and improved metabolic outcomes.

Significant Metabolic Improvements

The extended study data revealed substantial improvements in key health metrics for children with CAH. Among patients who were overweight or obese at baseline, 60% experienced clinically meaningful improvements in body mass index over the two-year treatment period. Additionally, 61% of patients who had insulin resistance at the start of treatment were no longer insulin resistant after two years of CRENESSITY therapy.

Hormone Control and Androgen-Related Benefits

CRENESSITY demonstrated sustained reductions in adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone levels, key markers of disease control in CAH. The treatment also showed improvements in outcomes associated with excess androgens, including reduced acne and improved androstenedione-to-testosterone ratios.

Reduced Glucocorticoid Dependence

A critical finding was CRENESSITY’s ability to enable lower, more physiologic glucocorticoid dosing while maintaining disease control. This reduction in glucocorticoid exposure is particularly significant for pediatric patients, as chronic high-dose glucocorticoid therapy can impair growth and development.

Market Impact and Clinical Significance

Congenital adrenal hyperplasia affects approximately 1 in 15,000 births, with limited treatment options beyond glucocorticoid replacement therapy. CRENESSITY represents a potential paradigm shift in CAH management by addressing both hormone control and the metabolic complications associated with traditional treatments.

The sustained two-year benefits support the drug’s potential as a long-term treatment option for pediatric CAH patients, addressing unmet medical needs in this rare disease population. These results strengthen Neurocrine’s position in the rare endocrine disorders market and could support regulatory submissions for pediatric indications.

---

Frequently Asked Questions

What is CRENESSITY and how does it work for CAH patients?

CRENESSITY (crinecerfont) is a treatment for congenital adrenal hyperplasia that helps control hormone levels while reducing the need for high-dose glucocorticoids, addressing both the underlying condition and treatment-related side effects.

When will CRENESSITY be available for pediatric CAH patients?

The drug is currently in clinical trials for pediatric indications. Neurocrine will likely use this two-year data to support regulatory submissions, though specific approval timelines have not been announced.

How does CRENESSITY compare to current CAH treatments?

Unlike traditional glucocorticoid-only therapy, CRENESSITY allows for lower glucocorticoid doses while maintaining disease control, potentially reducing growth impairment and metabolic complications common with current treatments.